Intravenous Immunoglobulin (IVIG) Market Size, Trends, Growth & Outlook

Intravenous Immunoglobulin (IVIG) Market by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre syndrome, and Others) and Type (IgG, IgA, IgM, IgE, and IgD): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

Industry: Life Science | Report ID: FAMI-00228 | Published on: Sep, 2019 | View: 1731 | Share:         

Request Sample Enquire Before Buying Request Discount

*As the coronavirus disease (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

  • Report Descripton
  • Table Of Content
  • Request Methodology
  • Request Customization

The global intravenous immunoglobulin (IGIV) market was valued at $8,995 million in 2017and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025.

Immunoglobulins (IGs), also referred to as antibodies, are glycoproteins produced by the blood plasma in response to foreign bodies or antigens. They are highly complex entities and are specific in their action. These immunoglobulins are obtained from blood through the process of fractionation and are purified for use in therapeutic and nontherapeutic areas.

Increase in prevalence of immunodeficiency and autoimmune diseases such as chronic inflammatory demyelinating polyneuropathy, hypogammaglobulinemia, & others and rise in adoption of immunoglobulin therapies for the treatment of various autoimmune disorders majorly drive the growth of the IVIG market. Furthermore, increase in approval of IVIG drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and other government agencies is expected to accelerate the growth of the IVIG industry. However, stringent government regulations toward the vigorous use of immunoglobulins, inflated cost of therapy, and high risk of side effects associated with the use of immunoglobulin intravenously are anticipated to hamper the market growth. On the contrary, significant investment in healthcare sector is expected to provide lucrative opportunities for the market growth in the near future.

The global intravenous immunoglobulin (IVIG) market is characterized based on application, type, and region. By application, the market is segmented into hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, Guillain–Barre syndrome, and others. Depending on type, it is classified into IgG, IgA, IgM, IgE, and IgD. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits for Intravenous Immunoglobulin Market:

    The report provides an in-depth analysis of the intravenous immunoglobulin market along with the current trends and future estimations to elucidate the imminent investment pockets.

    A comprehensive analysis of the factors that drive and restrict the market growth is provided in this study.

    The report provides a detailed quantitative analysis of the industry from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.

    An extensive analysis of the key segments of the industry helps to understand the trends in the intravenous immunoglobulin market globally.

    Key players and their strategies are provided to understand the competitive outlook of the industry.

Intravenous Immunoglobulin Key Market Segments:

By Application

    Hypogammaglobulinemia
    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Primary Immunodeficiency Disease
    Myasthenia Gravis
    Multifocal Motor Neuropathy
    Idiopathic Thrombocytopenic Purpura (ITP)
    Inflammatory Myopathies
    Specific Antibody Deficiency
    Guillain–Barre Syndrome
    Others

By Type

    IgG
    IgA
    IgM
    IgE
    IgD

By Region

    North America
        U.S.
        Canada
        Mexico
    Europe
        UK
        France
        Germany
        Italy
        France
        Austria
        Russia
        Rest of Europe
    Asia-Pacific
        Japan
        China
        India
        Australia
        Rest of Asia-Pacific
    LAMEA
        Brazil
        Argentina
        Turkey
        Saudi Arabia
        Rest of LAMEA

Key Players Profiled

    Baxter international Inc.
    CSL Ltd.
    Grifols, S.A.
    Octapharma AG
    Kedrion Biopharma Inc.
    LFB Group
    Biotest AG
    China Biologics Products, Inc.
    Takeda Pharmaceuticals
    Bayer AG

The other players of the intravenous immunoglobulin market included in the value chain analysis (but not profiled in the report) are as follows:

    Hualan Biological Engineering Inc.
    Omrix Biopharmaceuticals Ltd.
    Behring GmbH
    Shanghai RAAS Blood Products Co., Ltd.
    Option Care Enterprises, Inc.
    ADMA Biologics, Inc.
    BioScrip, Inc.
"
 

Get a sample pages of this report Click here

"CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Overview of Immunoglobulin

3.2.1. Patented products
3.2.2. Epidemiology and economic burden of chronic conditions

3.3. Key findings

3.3.1. Top Investment Pockets

3.4. Porters five forces analysis
3.5. Value chain analysis

3.5.1. Primary activities
3.5.2. Support activities

3.6. Market share analysis, 2017
3.7. Product scenario in intravenous immunoglobulin market
3.8. Government regulations and reimbursements

3.8.1. U.S.
3.8.2. Europe
3.8.3. France
3.8.4. Germany
3.8.5. Italy
3.8.6. China
3.8.7. Japan
3.8.8. India

3.9. Indications for immunoglobulin

3.9.1. U.S. FDA indications
3.9.2. EMA

3.10. Component analysis of immunoglobulin G (IgG)

3.10.1. IgG1
3.10.2. IgG2
3.10.3. IgG3
3.10.4. IgG4

3.11. Market dynamics

3.11.1. Drivers

3.11.1.1. Rise in prevalence of immunodeficiency diseases
3.11.1.2. Increase in adoption of immunoglobulin treatment
3.11.1.3. Growth in incidence of bleeding disorders

3.11.2. Restraints

3.11.2.1. Stringent government regulations
3.11.2.2. High cost of therapy

3.11.3. Opportunities

3.11.3.1. Opportunities in emerging economies
3.11.3.2. Development of cost-effective therapeutics through large-scale production

CHAPTER 4: IMMUNOGLOBULIN MARKET, BY APPLICATION

4.1. Overview

4.1.1. Market size and forecast

4.2. Hypogammaglobulinemia

4.2.1. Market size and forecast

4.3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)

4.3.1. Market size and forecast

4.4. Primary immunodeficiency diseases

4.4.1. Market size and forecast

4.5. Myasthenia Gravis

4.5.1. Market size and forecast

4.6. Multifocal motor neuropathy

4.6.1. Market size and forecast

4.7. Idiopathic thrombocytopenic purpura (ITP)

4.7.1. Market size and forecast

4.8. Inflammatory myopathies

4.8.1. Market size and forecast

4.9. Specific antibody deficiency

4.9.1. Market size and forecast

4.10. Guillain-Barre syndrome

4.10.1. Market size and forecast

4.11. Others

4.11.1. Market size and forecast

CHAPTER 5: IMMUNOGLOBULIN MARKET, BY PRODUCT

5.1. Overview

5.1.1. IGG

5.1.1.1. Key market trends

5.1.2. Clinical interpretations
5.1.3. IGA

5.1.3.1. Key Market Trends

5.1.4. Clinical interpretation
5.1.5. IGM

5.1.5.1. Key Market Trends

5.1.6. Clinical interpretation
5.1.7. IGE

5.1.7.1. Key Market Trend

5.1.8. Clinical interpretation
5.1.9. IGD

5.1.9.1. Key Market Trends

5.1.10. Clinical interpretation

CHAPTER 6: INTRVAENOUS IMMUNOGLOBULIN MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key trends and opportunities
6.2.2. North America market size & forecast, by application
6.2.3. North America market size & forecast, by country

6.2.3.1. U.S. market size & forecast
6.2.3.2. Canada market size & forecast
6.2.3.3. Mexico market size & forecast

6.3. Europe

6.3.1. Key trends and opportunities
6.3.2. Europe market size & forecast, by application
6.3.3. Europe market size & forecast for immunoglobulin market, by country

6.3.3.1. Germany market size & forecast
6.3.3.2. France market size & forecast
6.3.3.3. UK market size & forecast
6.3.3.4. Italy market size & forecast
6.3.3.5. Austria market size & forecast
6.3.3.6. Russia market size & forecast
6.3.3.7. Rest of Europe market size & forecast

6.4. Asia-Pacific

6.4.1. Key trends and opportunities
6.4.2. Asia-Pacific market size & forecast, by application
6.4.3. Asia-Pacific market size & forecast, by country

6.4.3.1. Australia market size & forecast
6.4.3.2. China market size & forecast
6.4.3.3. India market size & forecast
6.4.3.4. Japan market size & forecast
6.4.3.5. Rest of Asia-Pacific market size & forecast

6.5. LAMEA

6.5.1. Key trends and opportunities
6.5.2. LAMEA market size & forecast, by application
6.5.3. LAMEA market size & forecast, by country

6.5.3.1. Brazil market size & forecast
6.5.3.2. Saudi Arabia market size & forecast
6.5.3.3. Argentina market size & forecast
6.5.3.4. Turkey market size & forecast
6.5.3.5. Rest of LAMEA market size & forecast

CHAPTER 7: COMPANY PROFILES

7.1. BAXTER INTERNATIONAL INC.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. BAYER AG

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments

7.3. BIOTEST AG

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance

7.4. CHINA BIOLOGIC PRODUCTS, INC.

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance

7.5. CSL LIMITED

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance

7.6. GRIFOLS S.A.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. KEDRION BIOPHARMA INC.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments

7.8. LFB SA (LFB BIOTECHNOLOGIES SAS)

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance

7.9. OCTAPHARMA AG

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance

7.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments"
 

Select License Type
  • Single User License $5370 USD
  • Multi-User License $6450 USD
  • Corporate User License $8995 USD

Our Clients

  • +1 518-300-1215Mon-Fri, 24Hrs
  • [email protected]We reply within an hours
  • Albany,
    NY, USA.